Profile - To The Moon

Nackky

Posts · 37Posts · 37
Following · 0Following · 0
Followers · 0Followers · 0

- NackkyNackky
  ·2023-09-19
  $SUPER INC(SMCI)$ Thanks Thank you
  2.52K Comment
  Like
  Share
  Report
- NackkyNackky
  ·2023-09-18
  $ARM Holdings Ltd(ARM)$
  2.15K Comment
  1
  Share
  Report
- NackkyNackky
  ·2023-09-12
  $SUPER INC(SMCI)$
  A Bull Market Could Be Here: 2 Reasons to Buy Carvana Stock
  This troubled car retailer still possesses some favorable traits.
  A Bull Market Could Be Here: 2 Reasons to Buy Carvana Stock
  2.29K Comment
  Like
  Share
  Report
- NackkyNackky
  ·2023-09-12
  $SUPER INC(SMCI)$ $SUPER INC(SMCI)$ $SUPER INC(SMCI)$
  Crinetics Soars 73% As Lead Asset Succeeds in Phase 3 Trial for Acromegaly
  $Crinetics Pharmaceuticals(CRNX)$ added 73.89% pre-market Monday after announcing that its lead candidate, paltusotine, achieved the primary endpoint and all secondary endpoints in a Phase 3 trial for
  Crinetics Soars 73% As Lead Asset Succeeds in Phase 3 Trial for Acromegaly
  2.56K Comment
  1
  Share
  Report
- NackkyNackky
  ·2023-09-11
  $SUPER INC(SMCI)$ one//@Andrewinho:👏👏👏🚀🚀🚀
  Sorry, this post has been deleted
  2.24K Comment
  1
  Share
  Report
- NackkyNackky
  ·2023-09-11
  $Abercrombie & Fitch(ANF)$ $Netflix(NFLX)$
  2.52K Comment
  3
  Share
  Report
- NackkyNackky
  ·2023-09-02
  $VinFast Auto(VFS)$
  2.41K Comment
  1
  Share
  Report
- NackkyNackky
  ·2023-08-03
  $Straits Times Index(STI.SI)$
  1.92K Comment
  2
  Share
  Report
- NackkyNackky
  ·2023-08-03
  $Mosaic(MOS)$ $Apple(AAPL)$
  2.40K Comment
  3
  Share
  Report
- NackkyNackky
  ·2023-07-28
  Great ariticle, would you like to share it?
  @朝花夕拾NMC：
  $TSLA 20230728 277.5 CALL$
  $TSLA 20230728 277.5 CALL$
  3.07K 1
  2
  Share
  Report

Most Discussed

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"4149970614197132","uuid":"4149970614197132","gmtCreate":1686867502915,"gmtModify":1688024593569,"name":"Nackky","pinyin":"nackky","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/762717a8a75a2e9ebe6d882a1e937226","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":8,"headSize":173,"tweetSize":37,"questionSize":0,"limitLevel":999,"accountStatus":3,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":31,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":5,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"23f878ed27704312ae41c7f17e73b319-6","templateUuid":"23f878ed27704312ae41c7f17e73b319","name":"Annualised return","description":"Top 3%","bigImgUrl":"https://community-static.tradeup.com/news/6fbaa8e552e02eae8e6a2ce5d6566431","smallImgUrl":"https://community-static.tradeup.com/news/98862e418516dab972bed7aaf561dec6","grayImgUrl":"https://community-static.tradeup.com/news/3a5ca933a5695ed2e862b228f6c09ee5","redirectLinkEnabled":0,"redirectLink":"https://www.tigerbrokers.com.sg/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":5300}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":221560636051536,"gmtCreate":1695128603891,"gmtModify":1695128606435,"author":{"id":"4149970614197132","authorId":"4149970614197132","name":"Nackky","avatar":"https://community-static.tradeup.com/news/762717a8a75a2e9ebe6d882a1e937226","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4149970614197132","idStr":"4149970614197132"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/SMCI\">$SUPER INC(SMCI)$&nbsp;</a>Thanks Thank you","listText":"<a href=\"https://ttm.financial/S/SMCI\">$SUPER INC(SMCI)$&nbsp;</a>Thanks Thank you","text":"$SUPER INC(SMCI)$ Thanks Thank you","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/221560636051536","isVote":1,"tweetType":1,"viewCount":2520,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":220970211065960,"gmtCreate":1694969056587,"gmtModify":1694969058369,"author":{"id":"4149970614197132","authorId":"4149970614197132","name":"Nackky","avatar":"https://community-static.tradeup.com/news/762717a8a75a2e9ebe6d882a1e937226","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4149970614197132","idStr":"4149970614197132"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/ARM\">$ARM Holdings Ltd(ARM)$&nbsp;</a>","listText":"<a href=\"https://ttm.financial/S/ARM\">$ARM Holdings Ltd(ARM)$&nbsp;</a>","text":"$ARM Holdings Ltd(ARM)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/220970211065960","isVote":1,"tweetType":1,"viewCount":2153,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":218875454308456,"gmtCreate":1694462109430,"gmtModify":1694462112116,"author":{"id":"4149970614197132","authorId":"4149970614197132","name":"Nackky","avatar":"https://community-static.tradeup.com/news/762717a8a75a2e9ebe6d882a1e937226","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4149970614197132","idStr":"4149970614197132"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/SMCI\">$SUPER INC(SMCI)$&nbsp;</a>","listText":"<a href=\"https://ttm.financial/S/SMCI\">$SUPER INC(SMCI)$&nbsp;</a>","text":"$SUPER INC(SMCI)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/218875454308456","repostId":"2366353821","repostType":2,"repost":{"id":"2366353821","kind":"highlight","pubTimestamp":1694429033,"share":"https://ttm.financial/m/news/2366353821?lang=&edition=fundamental","pubTime":"2023-09-11 18:43","market":"us","language":"en","title":"A Bull Market Could Be Here: 2 Reasons to Buy Carvana Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2366353821","media":"Motley Fool","summary":"This troubled car retailer still possesses some favorable traits.","content":"<div>\n<p>After a gut-wrenching 98% drop in 2022, shares of Carvana (CVNA -1.41%) have bounced back tremendously this year, up over 900%. This performance is on the back of the 31% gain of the Nasdaq Composite,...</p>\n\n<a href=\"https://www.fool.com/investing/2023/09/10/bull-market-could-here-2-reasons-buy-carvana-stock/\">Web Link</a>\n\n</div>\n","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Bull Market Could Be Here: 2 Reasons to Buy Carvana Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Bull Market Could Be Here: 2 Reasons to Buy Carvana Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-09-11 18:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2023/09/10/bull-market-could-here-2-reasons-buy-carvana-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After a gut-wrenching 98% drop in 2022, shares of Carvana (CVNA -1.41%) have bounced back tremendously this year, up over 900%. This performance is on the back of the 31% gain of the Nasdaq Composite,...</p>\n\n<a href=\"https://www.fool.com/investing/2023/09/10/bull-market-could-here-2-reasons-buy-carvana-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4503":"景林资产持仓","CVNA":"Carvana Co.","BK4214":"汽车零售","BK4585":"ETF&股票定投概念","BK4548":"巴美列捷福持仓"},"source_url":"https://www.fool.com/investing/2023/09/10/bull-market-could-here-2-reasons-buy-carvana-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2366353821","content_text":"After a gut-wrenching 98% drop in 2022, shares of Carvana (CVNA -1.41%) have bounced back tremendously this year, up over 900%. This performance is on the back of the 31% gain of the Nasdaq Composite, which has entered bull-market territory following a huge decline last year. Boosting Carvana's stock was management's ability to restructure debt by extending maturities and substantially reducing interest payments this year and next. It looks like investors believe that the used car retailer has avoided filing for bankruptcy. But to be completely clear, Carvana is still an extremely risky business to own right now. There is a lot of uncertainty not only in the near term as it relates to the macroeconomic environment, but over the long term, with the company's ultimate success still in question. If that reality still doesn't scare you away, there are two compelling reasons to buy shares. Those interested in the most speculative growth tech stocks might be intrigued. Massive market One of the most obvious reasons to own shares has to do with the size of the domestic used-car industry. In 2021, 41 million vehicle transactions occurred, with a value of close to $900 billion. This is one of the largest retail markets across the broader economy. The industry is also extremely fragmented. The top-100 used car retailers command just 11% of the overall market. This means that there is ample opportunity for Carvana to grow its market share. For comparison's sake, in the home improvement industry, Home Depot, the biggest player, has 17% of the market. Dick's Sporting Goods, the leading athletic apparel and equipment retailer, has 14% share in its industry. It's anyone's guess what Carvana's ultimate market penetration will be. But if it can one day reach 10% of the used car industry, that would translate to a roughly tenfold rise in the company's annual unit volume over the 412,000 cars it sold in 2022. The insanely large addressable market that is sitting in front of Carvana is certainly why investors bid up shares over 3,200% between its initial public offering in April 2017 and its all-time high in August 2021. At that point, Carvana's market capitalization was more than $30 billion, which was indicative of the huge amount of optimism being priced in. That optimism was understandable. Carvana has created a superior customer experience in an outdated industry that is known for being a huge pain for car shoppers. If you're in the market for a used car, instead of going to a brick-and-mortar dealership that might have a limited inventory, an unpleasant salesperson, and a burdensome process, customers can go to Carvana's website, view thousands of options, and buy a car all in a few minutes. The car can be delivered to your house, and there's even a seven-day return policy. Low valuation A huge addressable market, coupled with a better customer experience, shows that Carvana has meaningful potential. But since the stock is currently 87% below its peak price, there is added upside for shareholders. Despite crushing the market this year, the beaten-down stock trades at a price-to-sales (P/S) multiple of 0.4 right now. Since going public, Carvana's average P/S ratio is 1.1. So clearly, the stock is incredibly cheap from a historical perspective. All else equal, a lower valuation means that the potential gains for investors are bigger. To be fair, Carvana has notable issues, with the most pressing being the company's troublesome financial situation. The problems have been exacerbated by unfavorable macro conditions. But for investors who believe that Carvana can get back to registering strong growth, while inching closer to profitability, it might be time to buy the stock.","news_type":1,"symbols_score_info":{"CVNA":1}},"isVote":1,"tweetType":1,"viewCount":2293,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":218861176041640,"gmtCreate":1694458770674,"gmtModify":1694458773422,"author":{"id":"4149970614197132","authorId":"4149970614197132","name":"Nackky","avatar":"https://community-static.tradeup.com/news/762717a8a75a2e9ebe6d882a1e937226","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4149970614197132","idStr":"4149970614197132"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/SMCI\">$SUPER INC(SMCI)$&nbsp;</a><a href=\"https://ttm.financial/S/SMCI\">$SUPER INC(SMCI)$&nbsp;</a><a href=\"https://ttm.financial/S/SMCI\">$SUPER INC(SMCI)$&nbsp;</a>","listText":"<a href=\"https://ttm.financial/S/SMCI\">$SUPER INC(SMCI)$&nbsp;</a><a href=\"https://ttm.financial/S/SMCI\">$SUPER INC(SMCI)$&nbsp;</a><a href=\"https://ttm.financial/S/SMCI\">$SUPER INC(SMCI)$&nbsp;</a>","text":"$SUPER INC(SMCI)$ $SUPER INC(SMCI)$ $SUPER INC(SMCI)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/218861176041640","repostId":"1155629873","repostType":2,"repost":{"id":"1155629873","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1694440135,"share":"https://ttm.financial/m/news/1155629873?lang=&edition=fundamental","pubTime":"2023-09-11 21:48","market":"us","language":"en","title":"Crinetics Soars 73% As Lead Asset Succeeds in Phase 3 Trial for Acromegaly","url":"https://stock-news.laohu8.com/highlight/detail?id=1155629873","media":"Tiger Newspress","summary":"$Crinetics Pharmaceuticals(CRNX)$ added 73.89% pre-market Monday after announcing that its lead candidate, paltusotine, achieved the primary endpoint and all secondary endpoints in a Phase 3 trial for","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/CRNX\">Crinetics Pharmaceuticals</a> added 73.89% pre-market Monday after announcing that its lead candidate, paltusotine, achieved the primary endpoint and all secondary endpoints in a Phase 3 trial for patients with the rare disease acromegaly.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/73fd1a760547b221377961286576b27b\" tg-width=\"808\" tg-height=\"630\"/></p><p>The PATHFNDR-1 study enrolled 58 adults with acromegaly, characterized by excessive growth hormone secretion. After switching from standard-of-care, they received once-daily oral paltusotine or a placebo for 36 weeks .</p><p>The trial met statistical significance (p&lt;0.0001) for the primary endpoint as 83% of patients on paltusotine maintained an insulin-like growth factor 1 (IGF-1) level ≤ 1.0 times the upper limit of normal, compared to 4% on placebo.</p><p>All secondary endpoints of the trial also achieved statistical significance. Regarding safety, the proportion of patients with at least one treatment-emergent adverse event (TEAE) stood at 80% and 100% for the on-drug and off-drug arms, respectively.</p><p>Crinetics intends to seek U.S. regulatory approval for paltusotine in 2024, subject to positive results from PATHFNDR-2, an ongoing Phase 3 study for the drug targeted at untreated acromegaly patients. That trial is fully enrolled and is expected to generate early data in Q1 2024.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crinetics Soars 73% As Lead Asset Succeeds in Phase 3 Trial for Acromegaly</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrinetics Soars 73% As Lead Asset Succeeds in Phase 3 Trial for Acromegaly\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2023-09-11 21:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/CRNX\">Crinetics Pharmaceuticals</a> added 73.89% pre-market Monday after announcing that its lead candidate, paltusotine, achieved the primary endpoint and all secondary endpoints in a Phase 3 trial for patients with the rare disease acromegaly.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/73fd1a760547b221377961286576b27b\" tg-width=\"808\" tg-height=\"630\"/></p><p>The PATHFNDR-1 study enrolled 58 adults with acromegaly, characterized by excessive growth hormone secretion. After switching from standard-of-care, they received once-daily oral paltusotine or a placebo for 36 weeks .</p><p>The trial met statistical significance (p&lt;0.0001) for the primary endpoint as 83% of patients on paltusotine maintained an insulin-like growth factor 1 (IGF-1) level ≤ 1.0 times the upper limit of normal, compared to 4% on placebo.</p><p>All secondary endpoints of the trial also achieved statistical significance. Regarding safety, the proportion of patients with at least one treatment-emergent adverse event (TEAE) stood at 80% and 100% for the on-drug and off-drug arms, respectively.</p><p>Crinetics intends to seek U.S. regulatory approval for paltusotine in 2024, subject to positive results from PATHFNDR-2, an ongoing Phase 3 study for the drug targeted at untreated acromegaly patients. That trial is fully enrolled and is expected to generate early data in Q1 2024.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRNX":"Crinetics Pharmaceuticals Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1155629873","content_text":"Crinetics Pharmaceuticals added 73.89% pre-market Monday after announcing that its lead candidate, paltusotine, achieved the primary endpoint and all secondary endpoints in a Phase 3 trial for patients with the rare disease acromegaly.The PATHFNDR-1 study enrolled 58 adults with acromegaly, characterized by excessive growth hormone secretion. After switching from standard-of-care, they received once-daily oral paltusotine or a placebo for 36 weeks .The trial met statistical significance (p<0.0001) for the primary endpoint as 83% of patients on paltusotine maintained an insulin-like growth factor 1 (IGF-1) level ≤ 1.0 times the upper limit of normal, compared to 4% on placebo.All secondary endpoints of the trial also achieved statistical significance. Regarding safety, the proportion of patients with at least one treatment-emergent adverse event (TEAE) stood at 80% and 100% for the on-drug and off-drug arms, respectively.Crinetics intends to seek U.S. regulatory approval for paltusotine in 2024, subject to positive results from PATHFNDR-2, an ongoing Phase 3 study for the drug targeted at untreated acromegaly patients. That trial is fully enrolled and is expected to generate early data in Q1 2024.","news_type":1,"symbols_score_info":{"CRNX":1.1}},"isVote":1,"tweetType":1,"viewCount":2563,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":218786746962136,"gmtCreate":1694440644899,"gmtModify":1694440647199,"author":{"id":"4149970614197132","authorId":"4149970614197132","name":"Nackky","avatar":"https://community-static.tradeup.com/news/762717a8a75a2e9ebe6d882a1e937226","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4149970614197132","idStr":"4149970614197132"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/SMCI\">$SUPER INC(SMCI)$&nbsp;</a>one//<a href=\"https://ttm.financial/U/3581563418944392\">@Andrewinho</a>:👏👏👏🚀🚀🚀","listText":"<a href=\"https://ttm.financial/S/SMCI\">$SUPER INC(SMCI)$&nbsp;</a>one//<a href=\"https://ttm.financial/U/3581563418944392\">@Andrewinho</a>:👏👏👏🚀🚀🚀","text":"$SUPER INC(SMCI)$ one//@Andrewinho:👏👏👏🚀🚀🚀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/218786746962136","repostId":"1119056374","repostType":4,"isVote":1,"tweetType":1,"viewCount":2243,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":218769178898560,"gmtCreate":1694436163489,"gmtModify":1694436166351,"author":{"id":"4149970614197132","authorId":"4149970614197132","name":"Nackky","avatar":"https://community-static.tradeup.com/news/762717a8a75a2e9ebe6d882a1e937226","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4149970614197132","idStr":"4149970614197132"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/ANF\">$Abercrombie &amp; Fitch(ANF)$&nbsp;</a><a href=\"https://ttm.financial/S/NFLX\">$Netflix(NFLX)$&nbsp;</a><v-v data-views=\"0\"></v-v>","listText":"<a href=\"https://ttm.financial/S/ANF\">$Abercrombie &amp; Fitch(ANF)$&nbsp;</a><a href=\"https://ttm.financial/S/NFLX\">$Netflix(NFLX)$&nbsp;</a><v-v data-views=\"0\"></v-v>","text":"$Abercrombie & Fitch(ANF)$ $Netflix(NFLX)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/218769178898560","isVote":1,"tweetType":1,"viewCount":2515,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":215341713354784,"gmtCreate":1693604484101,"gmtModify":1693604486635,"author":{"id":"4149970614197132","authorId":"4149970614197132","name":"Nackky","avatar":"https://community-static.tradeup.com/news/762717a8a75a2e9ebe6d882a1e937226","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4149970614197132","idStr":"4149970614197132"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/VFS\">$VinFast Auto(VFS)$&nbsp;</a>","listText":"<a href=\"https://ttm.financial/S/VFS\">$VinFast Auto(VFS)$&nbsp;</a>","text":"$VinFast Auto(VFS)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/215341713354784","isVote":1,"tweetType":1,"viewCount":2405,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":204673710653632,"gmtCreate":1691002538512,"gmtModify":1691002541305,"author":{"id":"4149970614197132","authorId":"4149970614197132","name":"Nackky","avatar":"https://community-static.tradeup.com/news/762717a8a75a2e9ebe6d882a1e937226","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4149970614197132","idStr":"4149970614197132"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/STI.SI\">$Straits Times Index(STI.SI)$&nbsp;</a><v-v data-views=\"1\"></v-v>","listText":"<a href=\"https://ttm.financial/S/STI.SI\">$Straits Times Index(STI.SI)$&nbsp;</a><v-v data-views=\"1\"></v-v>","text":"$Straits Times Index(STI.SI)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/204673710653632","isVote":1,"tweetType":1,"viewCount":1924,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":204664864424184,"gmtCreate":1691000242184,"gmtModify":1691000245120,"author":{"id":"4149970614197132","authorId":"4149970614197132","name":"Nackky","avatar":"https://community-static.tradeup.com/news/762717a8a75a2e9ebe6d882a1e937226","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4149970614197132","idStr":"4149970614197132"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/MOS\">$Mosaic(MOS)$&nbsp;</a><a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$&nbsp;</a><v-v data-views=\"0\"></v-v>","listText":"<a href=\"https://ttm.financial/S/MOS\">$Mosaic(MOS)$&nbsp;</a><a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$&nbsp;</a><v-v data-views=\"0\"></v-v>","text":"$Mosaic(MOS)$ $Apple(AAPL)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/204664864424184","isVote":1,"tweetType":1,"viewCount":2400,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":202536540897368,"gmtCreate":1690485931588,"gmtModify":1690485936308,"author":{"id":"4149970614197132","authorId":"4149970614197132","name":"Nackky","avatar":"https://community-static.tradeup.com/news/762717a8a75a2e9ebe6d882a1e937226","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4149970614197132","idStr":"4149970614197132"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/202536540897368","repostId":"202511885426880","repostType":1,"repost":{"id":202511885426880,"gmtCreate":1690481473432,"gmtModify":1690481473490,"author":{"id":"3482384284219919","authorId":"3482384284219919","name":"朝花夕拾NMC","avatar":"https://static.laohu8.com/a7577fa2b065001f43de50c6bb331306","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3482384284219919","idStr":"3482384284219919"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/OPT/TSLA 20230728 277.5 CALL\">$TSLA 20230728 277.5 CALL$&nbsp;</a>","listText":"<a href=\"https://laohu8.com/OPT/TSLA 20230728 277.5 CALL\">$TSLA 20230728 277.5 CALL$&nbsp;</a>","text":"$TSLA 20230728 277.5 CALL$","images":[{"img":"https://static.tigerbbs.com/e5e5f0bf9d14262684921dab1f10d708","width":"1086","height":"1713"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/202511885426880","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":3074,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}